Luye to provide investors with a dose of diversification
Luye Pharma Group started premarketing a $800m Hong Kong IPO on June 11, with those on the deal confident that investor demand will be red hot.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: